Pipeline Innovation & Drug Design

Novel target, conserved sequence, low mutation susceptibility. In vitro: high inhibitory activity against coronaviruses (including SARS-CoV-2).

Critical for epidemic control as a universal preventive when vaccines/meds are unavailable.

Ideal for elderly/immunocompromised: non-immune-dependent, rapid-acting, blocks infection effectively.

Activates cellular immunity: Suitable for immunocompromised individuals.

Less strict storage vs. inactivated/mRNA vaccines.

High-efficiency chemical synthesis enables large-scale stable production.

HY3003 Project (a joint initiative by Hybio & iCarbonX). AI-integrated peptide chip tech identifies novel GLP-1R/GIPR/GCGR triple-target agonist. Preclinical screening and API process development completed; now in API pilot production. Research ongoing for monthly long-acting, oral formulations, plus non-clinical evaluations (pharmacodynamics, pharmacokinetics, safety).

HY3003 Long-Acting Sustained-Release Formulation. Monthly injectable leveraging Hybio’s long-acting delivery platform. Biocompatible excipients with optimized formulation enable sustained peptide release.

Advantages vs. Marketed GLP-1 Agonists. Current max dosing interval: once weekly. Plasma peaks cause significant gastrointestinal side effects (30% discontinue within 6 weeks; 65% within 1 year; 85%+ within 2 years). HY3003: monthly dosing reduces frequency. Reservoir-release maintains stable concentrations, lowering plasma peaks.